United Therapeutics Corporation vs Cytokinetics, Incorporated: Examining Key Revenue Metrics

Biotech Revenue Trends: United Therapeutics vs. Cytokinetics

__timestampCytokinetics, IncorporatedUnited Therapeutics Corporation
Wednesday, January 1, 2014469400001288519000
Thursday, January 1, 2015286580001465761000
Friday, January 1, 20161064070001598800000
Sunday, January 1, 2017133680001725300000
Monday, January 1, 2018315010001627800000
Tuesday, January 1, 2019268680001448800000
Wednesday, January 1, 2020558280001483300000
Friday, January 1, 2021704280001685500000
Saturday, January 1, 2022945880001936300000
Sunday, January 1, 202375300002327500000
Loading chart...

Cracking the code

A Tale of Two Biotechs: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, United Therapeutics Corporation and Cytokinetics, Incorporated have carved distinct paths over the past decade. From 2014 to 2023, United Therapeutics consistently demonstrated robust revenue growth, peaking in 2023 with a staggering 2.3 billion USD, marking an impressive 80% increase from its 2014 figures. In contrast, Cytokinetics experienced a more volatile journey, with revenues fluctuating significantly. Notably, their highest revenue was recorded in 2016, but by 2023, it had dwindled to just 7.5 million USD, a stark 84% drop from their peak. This divergence highlights the contrasting strategies and market responses of these two companies. As the biotech sector continues to evolve, these trends offer valuable insights into the resilience and adaptability required to thrive in this competitive landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025